Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 6207412
Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells
expired -
US 6207147
Cancer immunotherapy using tumor cells combined with mixed lymphocytes
expired -
US 6207821
Long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis
expired -
US 6207451
Mammalian muscle construct and method for producing same
expired -
US 6207403
Kinesin motor modulators derived from the marine sponge Adocia
expired -
US 6207199
Process for making a particulate support matrix for making a rapidly dissolving dosage form
expired -
US 6207186
Lamellar gels and methods for making and using
expired -
US 6204245
Treatment of narcolepsy with immunosuppressants
expired -
US 6203793
Compositions and methods for treating thermal injury
expired -
US 6203778
Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
expired -
US 6203991
Inhibition of smooth muscle cell migration by heme oxygenase I
expired -
US 6203787
Treating tumors using implants comprising combinations of allogeneic cells
expired -
US 6200599
Ortho ester lipids
expired -
US 6200597
Formulation and use of carotenoids in treatment of cancer
expired -
US 6201165
Transgenic animal models for cardiac hypertrophy and methods of use thereof
expired -
US 6201107
Cystic fibrosis gene
expired -
US 6200811
Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein
expired -
US 6197541
Recombinant thrombin receptors and assays using them
expired -
US 6197497
Immunoassay for herpes simplex virus
expired -
US 6197586
Chondrocyte-like cells useful for tissue engineering and methods
expired -
US 6197754
Suppression of tumor growth by a mini-E1A gene
expired -
US 6197345
Thrombolytic agents and methods of treatment for thrombosis
expired -
US 6194421
Inhibitors of metazoan parasite proteases
expired -
US 6193965
Oncoprotein kinase
expired -
US 6194176
Recombinant expression of proteins from secretory cell lines
expired -
US 6194481
Mechanically strong and transparent or translucent composites made using zirconium oxide nanoparticles
expired -
US 6194206
Use of oligonucleotide telomerase inhibitors to reduce telomere length
expired -
US 6193963
Method of treating tumor-bearing patients with human plasma hyaluronidase
expired -
US 6190723
Neutralization of food allergens by thioredoxin
expired -
US 6190894
Method and compositions for disrupting the epithelial barrier function
expired -
US 6191103
Methods for enhancing thrombolysis in a mammal
expired -
US 6191269
Selective induction of cell death by delivery of amino-terminal interleukin-1-.alpha. pro-piece polypeptide
expired -
US 6187337
Rapidly dissolving dosage form
expired -
US 6187814
Treatment of skin conditions with FXR activators
expired -
US 6187296
Lysine decarboxylase inhibitors for the prevention and treatment of periodontal disease
expired -
US 6183961
Methods and compositions for regulating cell cycle progression
expired -
US 6184254
Methods of identifying modulators of perivascular sensory nerve Ca2+ receptors
expired -
US 6184224
Antitumor dibenzofluorene derivatives
expired -
US 6184215
Treatment of skin conditions with oxysterol activators of LXR.alpha.
expired -
US 6183772
Doped colorimetric assay liposomes
expired -
US 6183727
Use of long-wavelength electromagnetic radiation and photoprotective tumor localizing agents for diagnosis
expired -
US 6180142
Reduction of surfactant inactivation in pulmonary surfactant therapy
expired -
US 6177272
Method for treating vascular proliferative diseases with p27 and fusions thereof
expired -
US 6177104
Particulate support matrix for making a rapidly dissolving dosage form
expired -
US 6177547
Antibodies to P-selectin glycoprotein ligand
expired -
US 6174872
Method for treating allergic lung disease
expired -
US 6174871
Gene therapies for enhancing cardiac function
expired -
US 6172212
Pea3 is a tumor suppressor
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory